APG808 resulted in a rapid and durable decrease from baseline in FeNO and pSTAT6 measurements throughout the 12 weeks.

The inclusion of BATURA study results in the US prescribing information builds upon the previous MANDALA Phase III trial in adult patients with moderate to severe asthma. 3 The MANDALA and BATURA ...

Questions remain on whether there are links between patients with asthma and RA, including heterogeneity of disease.

In many patients, annual short-acting beta2-agonist prescription fulfillment is indicative of uncontrolled disease and increased incidence of exacerbations. Credit: Getty Images. Short-acting beta ...

Please provide your email address to receive an email when new articles are posted on . Risk and annualized rate of severe exacerbations dropped with as-needed use of albuterol-budesonide vs.

The FDA has accepted for review the NDA for Chiesi’s single inhaler triple therapy for the maintenance treatment of asthma in adults.

This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they ...

Medically reviewed by Susan Russell, MD Key Takeaways If asthma is not well-controlled, it can cause airway remodeling and ...

Multiple doses of APG808 resulted in rapid suppression of FeNO, a biomarker of Type 2 inflammation associated with exacerbations in asthma, with a robust maximal FeNO decrease from baseline of 53% ...

If you are wheezing, coughing, or having extreme shortness of breath, you may be having an asthma attack.

People with severe asthma may not respond to the usual treatment. Researchers have examined what drives the inflammatory response in severe asthmatics at a molecular level and their findings may lead ...

AIRSUPRA’s US Prescribing Information now includes clinically meaningful evidence from the BATURA study in patients with mild asthma.1 The BATURA Phase IIIb trial, which evaluated severe exacerbation ...